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The thrombolytic and systemic effects of BM 06.022 were evalu-
ated and compared with those of alteplase, anistreplase, streptoki· 
nase and urokinase in a canine model of coronary artery throm-
bosis. BM 06.022 consists of the kringle-2 and protease domains of 
human tissue plasminogen activator (t-PA) and is unglycosylated 
because of its expression in EscherichiJz coli cells. Thrombus 
formation in anestbetized open chest dogs was induced by electri-
cal injury to the intimal surface of the left circumflex coronary 
artery at a high level site of obstruction. 
In heparinized dogs, none of six vehicle-treated animals exhib· 
ited reperfusion. Reperfusion was achieved in four of six dogs at 
18.3 ± 6 min after intravenous bolus injection of 140 kU/kg 
(0.24 mg/kg) of BM 06.022, whereas four of six dogs exhibited 
reperfusion later (p < 0.05) at 76.5 ± 16.1 min during infusion of 
1.33 mg/kg of alteplase (0.13 mg/kg as initial bolus injection, 
followed by 0.66 mg/kg over 1 h and 0.53 mglkg over 2 b). 
Significantly later (p < 0.05) reperfusion than that achieved with 
BM 06.022 was achieved in five of six dogs at 57.8 ± 12.1 min after 
Thrombolytic therapy is an effective treatment for acute 
myocardial infarction due to an obstructed coronary artery. 
Recombinant tissue-type plasminogen activator (rt-PA) has 
been shown to effectively dissolve coronary artery thrombi 
(1), with a resultant improvement in myocardial function (2) 
and an increase in survival after myocardial infarction (3). 
The exact time course of cardiac tissue death in humans is 
not known precisely, but analysis of large clinical trials 
suggests that the more rapid the achieved patency of the 
obstructed coronary artery after the onset of symptoms, the 
greater the increase in survival rate (4). Therefore, throm-
bolytic treatment should be initiated in a time frame within 
which tissue salvage is still possible. Furthermore, coronary 
artery recanalization should be accomplished as rapidly as 
possible. 
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intravenous injection of 0.4 U/kg of anistreplase. Streptokinase 
(21,000 IU/kg over 60 min) and urokinase (20,000 IU/kg as an 
intravenous bolus injection, followed by 20,000 IU/kg over 89 min) 
each induced reperfusion in three of six dogs but at 67 ± 12 and 
84.3 ± 17.1 min (p < 0.05 vs. BM 06.022), respectively. 
Residual fibrinogen was lower (p < 0.05) in the anistreplase 
(4.3 ± 0.2%) and urokinase (26.2 ± 11.5%) groups compared 
with the BM 06.022 group (95.7 ± 3.7%) but was similar in the 
alteplase (97 .2 ± 3.3%) and streptokinase (101.1 ± 3.5%) groups. 
Bleeding time at 90 min was similar in the alteplase (3.8 ± 
0.9 min) and BM 06.022 (2.5 ± 0.2 min) groups but was longer 
(p < 0.05) in the anistreplase (13.5 ± 4.3 min), streptokinase 
(9.5 ± 2.5 min) and urokinase (6.3 ± 2 min) groups. 
Therefore, BM 06.022 might achieve rapid and high rate 
reperfusion after intravenous bolus injection without causing a 
severe systemic lytic state. 
(JAm Coli Cardiol1992,·19:433-40) 
The clearance of rt-PA through the liver is rapid, resulting 
in a dominant half-life in plasma of 3 to 6 min in patients (5) , 
which requires continuous infusion of the drug to maintain 
therapeutic blood levels. This rapid clearance constitutes a 
disadvantage because of the large amount of drug required 
and the need for infusion. Furthermore, it complicates the 
feasibility of prehospital administration as a single bolus 
injection, which could help to shorten the time from onset of 
symptoms to initiation of therapy. A recombinant plasmino-
gen activator with a slower clearance from the blood could 
facilitate a single intravenous bolus injection. 
BM 06.022 consists of the kringle-2 and protease domains 
of human tissue plasminogen activator (t-PA). Because BM 
06.022 is expressed in Escherichia coli cells, the resulting 
protein is unglycosylated. The thrombolytic effects of BM 
06.022 after intravenous bolus injection were demonstrated 
in a rabbit model of venous thrombosis (6) and a canine 
stenotic model of coronary artery thrombosis (7). In these 
experimental in vivo studies, because of its improved phar-
macokinetic properties (6,7), BM 06.022 was found to have 
about five times the thrombolytic potency of alteplase. 
Intravenous bolus injection of 140 kU/kg of BM 06.022 was 
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shown to be as effective as a standard treatment regimen of 
rt-PA with intravenous infusion of 1 mg/kg of rt-PA over 
90 min (7). 
In addition to rt-PA, other thrombolytic agents such as 
streptokinase, urokinase and anistreplase have been shown 
to be beneficial in the treatment of acute myocardial infarc-
tion (8-10). Therefore, the aim of the present study was to 
evaluate the thrombolytic and systemic effects of BM 06.022 
after intravenous bolus injection in direct comparison with 
the standard treatment effects of alteplase, streptokinase, 
urokinase and anistreplase. Additionally, alteplase was ad-
ministered as an intravenous bolus injection in another 
group. 
The model used in the present study is characterized by a 
level of obstruction in the coronary artery (almost complete 
elimination of the reactive hyperemia) that consistently 
elicits reocclusion after successful thrombolysis and restricts 
the maximal return of blood flow, thus mimicking the situa-
tion in patients with a high risk of flow deterioration after 
successful thrombolysis. To evaluate the quality of reperfu-
sion with BM 06.022 in the setting of a lower risk, we also 
investigated BM 06.022 in this model with a less severe 
degree of obstruction. 
Methods 
Animal model. Adult beagle dogs of either gender (10.5 to 
17.7 kg; n = 48) were anesthetized with intravenous sodium 
pentobarbital (35 mg/kg body weight), intubated and artifi-
cially ventilated. The right femoral vein was cannulated for 
intravenous administration of drugs and withdrawal of blood 
samples. Catheters were placed in the jugular veins for fluid 
and supplemental anesthetic administration and infusion of 
fibrinolytic agents. A thoracotomy was performed at the left 
fifth intercostal space and the heart was suspended in a 
pericardial cradle. A 2-cm section of the left circumflex 
coronary artery was isolated and instrumented as recently 
described (7). An electromagnetic flow probe was used 
for continuous blood flow monitoring. Blood pressure and 
coronary blood flow were recorded continuously on a 
Schwarzer polygraph. 
The left circumflex coronary artery thrombus was pro-
duced by the method originally described by Romson et al. 
(11) as modified by Shebuski et al. (12) and Kopia et al. (13). 
Briefly, the adjustable screw occluder on the left circumflex 
coronary artery was tightened to create a critical stenosis 
just sufficient (about 90%) to eliminate the reactive hypere-
mic response in seven of eight groups and to eliminate about 
50% of the reactive hyperemic response to a 20-s occlusion 
of the left circumflex coronary artery in another group. A 
150-JLA continuous anodal current was applied to the coro-
nary artery electrode and maintained until left circumflex 
coronary artery blood flow decreased to and remained at 
0 mllmin for 3 min. Electrical stimulation was delivered for 
;?: 15 min. The thrombus was allowed to age for 60 min. This 
experimental study with dogs conformed to the "Position of 
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the American Heart Association on Research Animal Use" 
adopted November 11, 1984. 
Thrombolytic agents. The recombinant wild-type t-PA used 
was alteplase, purchased from Dr. Karl Thomae GmbH. The 
concentration of functionally active alteplase was determined 
by a spectrophotometric assay (14) using CHROMOZYM PL 
as chromogenic substrate, Glu-plasrninogen and CNBr split 
products of human fibrinogen for stimulation (15). Alteplase 
had a specific activity of800 kU/mg (1,000 U = kU). 
BM 06.022 was produced in E. coli, as recently described 
(6,7, 16). The primary structure of the protein consisted of 
355 amino acids and comprised theN-terminal amino acids 
[1 to 3], attached to the complete kringle-2 domain [176 to 
275] and the protease amino acid sequence [276 to 527] of 
human t-PA. The final product was unglycosylated because 
of the E. coli expression (16) and was totally of the single-
chain form (MW 39 kD). BM 06.022 was manufactured by 
Boehringer Mannheim GmbH and was available as lyophili-
sate. Its specific activity was 578 kU/mg. 
For control experiments, vehicle solution was used. 
Anistreplase was obtained from Beecham-Wiilfing. Strep-
tokinase from Pfrimmer-Kabi and urokinase from Medac 
GmbH. 
Experimental protocol. Sodium heparin was infused in-
travenously at a rate of 1,000 IU/h, beginning 90 min after 
occlusion of the left circumflex coronary artery and was 
added to the continuous fluid substitution with 3 ml 0.9% 
saline solution/kg per h. One hour after thrombus formation, 
treatment was initiated. BM 06.022, alteplase, anistreplase 
or vehicle was administered as a single intravenous bolus 
injection over 1 min. BM 06.022 was injected at a dose of 
140 kU/kg (0.24 mg/kg), alteplase at a dose of 800 kU/kg 
(1 mg/kg), anistreplase at a dose of 0.4 U/kg (0.4 mg!kg) and 
vehicle at a volume dose of 0.14 ml/kg. Additionally, al-
teplase was administered in a total dose of 1.33 mg/kg given 
as an initial bolus dose of 0.13 mg/kg over 2 min, followed by 
infusion of 0.67 mg/kg over 1 hand then 0.26 mg/kg in each 
of the next 2 h. Streptokinase was infused continuously over 
60 min at a total dose of 21,000 U/kg. Urokinase was 
administered as an initial intravenous bolus injection of 
20,000 U/kg over 1 min, followed by an 89 min infusion of 
20,000 U/kg. 
In these seven treatment groups, consisting of six animals 
each, the reactive hyperemic response was reduced by 90%. 
An additional group was formed with a reactive hyperemic 
response reduced by about 50% to mimic a situation in 
patients with a lower risk for flow deterioration; the six dogs 
in this group received 140 kU/kg BM 06.022 as a single 
intravenous bolus injection over 1 min. 
Measurements. Mean and phasic left circumflex coronary 
artery blood flow was monitored continuously and for 3 h 
after administration of fibrinolytic drugs or vehicle. The time 
to reperfusion was defined as the time from onset of treat-
ment to the time of return of coronary blood flow to 33% of 
the control level before occlusion. This definition was deter-
mined from two other models with different degrees of 
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Table 1. Characteristics of Thrombosis, Thrombolysis and Reocclusion in the Canine Model of Coronary Artery Thrombosis 
Residual Incidence of Incidence of 
Reactive Time to Reperfusion Time to Reocclusion Time to 
Fibrinolytic Hyperemia Occlusion (reperfused/ Reperfusion (reoccluded/ Reocclusion 
Agent (% of baseline) (min) total) (min) reperfused) (min) 
Vehicle 10.2 ± 2.2 50.3 ± 17.3 0/6 
BM 06.022 10.6 ± 2.8 49.3 ± 8.9 4/6 18.3 ± 6.0 4/4 4.0 ± 1.5 
Alteplase 
Injection 9.0 ± 1.9 38.3 ± 4.8* 2/6 35 .5 (19/52) 2/2 47.5 (4/91) 
Infusion 13.5 ± 2.4 64.2 ± 20.5 4/6 76.5 ± 16.1* 4/4 4.3 ± 1.0 
Anistreplase 5.7 ± 0.9* 61.7 ± 14.2 516 57.8 ± 12.1* 4/5 19.8 ± 8.0* 
Streptokinase 7.5 ± 0.7 58.8 ± 12.0 3/6 67.0 ± 12.0* 3/3 5.0 ± 1.2 
Urokinase 11.1 ± 1.8 48.5 ± 9.9 3/6 84.3 ± 17.1* 3/3 15.3 ± 8.8 
BM 06.022 46.1 ± 3.9 50.3 ± 17.3 6/6 25.8 ± 5.0 5/6 6.4 ± 2.7 
*p < 0.05 compared with BM 06.022 (10.6% residual reactive hyperemia) by the Student t test. Data represent mean values ± SEM or fractional data; n = 
6/group. 
stenosis (17,18). Reocclusion ofreperfused coronary arteries 
was defined as a return of coronary blood flow to zero-flow 
level, regardless of how long this level lasted. Time to 
reocclusion was the interval from the time of reperfusion to 
the time that blood flow reached the zero-flow level. Cyclic 
flow reductions were defined as the number of cycles with 
reperfusion followed by complete reocclusion. The cumula-
tive patency time represents the sum of time intervals in 
which the coronary artery was patent as determined by 
measurement of blood flow. At termination of the experi-
ments (3 h after initiation of treatment), the left circumflex 
coronary artery segment was excised and opened longitudi-
nally. The residual thrombus was removed and its wet 
weight determined. 
Blood analysis. Venous blood samples for hemostasis 
measurements were collected in 0.01 M of citrate and 
transferred to tubes containing PPACK (D-Phe-Pro-Arg-
C'H2Cl) at a final concentration of 2 p.M (19). Bleeding time 
was determined in an open label fashion 90 min after 
initiation of treatment with a monoblade spring-loaded de-
vice (SIMPLATE, Organon Teknika) on the shaved hindleg 
(20). Blood samples for measurement of platelet count were 
drawn on ethylenediamine tetraacetic acid. Platelet aggrega-
tion induced by adenosine diphosphate (ADP) (100 p.M) and 
collagen (5 ~-tg/ml) in platelet-rich plasma was studied as 
previously described (11). Fibrinogen was determined with a 
clotting rate assay, originally described by Clauss (21). 
Plasminogen and alpha2-antiplasmin were measured with 
chromogenic substrate S-2251 assays (22-24). 
Citrated blood samples for determination of plasma con-
centration offunctionally active BM 06.022 or alteplase were 
taken before and repeatedly after administration and ana-
lyzed as recently described (7). The area under the plasma 
concentration versus time curve from time zero to the last 
data point was calculated with use of the trapezoidal rule. 
Total plasma clearance was calculated by dividing dose by 
the area under the concentration versus time curve. Half-life 
values were calculated by dividing the natural logarithm of 2 
(ln2) by the rate constant that was obtained by linear 
regression of the log-transformed postinjection data. 
Statistical analysis. Frequency data are presented in frac-
tional form. Data described by continuous variates are 
reported as the mean values ± SEM. The significance of 
differences between groups or within one treatment group 
was determined with the Student t test for unpaired or paired 
values, respectively. The null hypothesis was rejected only 
when the probability (p) of the calculated statistic was 
<0.05. 
Results 
Thrombolytic effects (Tables 1 and 2). Electrical stimula-
tion of the left circumflex coronary artery consistently 
produced thrombus formation at the times indicated in Table 
1. Baseline coronary blood flow before thrombosis was 
comparable in all treatment groups (Table 2). Vehicle-
treated dogs did not exhibit spontaneous reperfusion during 
the 3-h observation period. Depending on the degree of the 
residual reactive hyperemia (10.6% vs. 46.1 %), reperfusion 
after injection of 140 kU/kg (0.24 mg/kg) of BM 06.022 
occurred in four of six or six of six dogs, respectively. The 
reperfusion rate was lowest (two of six dogs) after alteplase 
injection and highest (five of six dogs) after anistreplase, 
whereas streptokinase and urokinase each induced reperfu-
sion in three of six dogs (Table 1). Alteplase achieved 
reperfusion in four of six dogs during infusion. The time to 
reperfusion was shorter (p < 0.05) in the BM 06.022-group 
with 10.6% residual reactive hyperemia than in the alteplase, 
anistreplase, streptokinase and urokinase groups (Table 1). 
Reocclusion occurred in nearly all dogs exhibiting reper-
fusion, but occurred later in the anistreplase (p < 0.05) than 
in the BM 06.022 group (Table 1). The maximal measured 
coronary blood flow after successful reperfusion did not 
significantly differ between the BM 06.022 group and the 
other groups with 90% reduction of reactive hyperemia, but 
was higher (p < 0.05) at 50% than at 90% reduction of 
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Table 2. Characteristics of Left Circumflex Coronary Artery Blood Flow and Residual Thrombus Wet Weight in the Canine Model of 
Coronary Artery Thrombosis 
Blood Flow (ml/min) 
Number of Cumulative Residual 
Before Maximum Mter Cyclical Flow Patency Thrombus Wet 
Fibrinolytic Agent Thrombosis Reperfusion* Reductions* Time (min) Weight (mg) 
Vehicle 19.8 ± 1.1 9.7 ± 1.3t 
BM 06.022 (10.6% RRH) 20.8 ± 1.1 12.5 ± 3.2 4.3 ± 0.6 47.5 ± 13.1 6.1 ± 1.1 
Alteplase 
Injection 19.3 ± 1.2 8.5 (8/9) 1.5 (2/1) 65 (4/126) 5.2 ± 1.2 
Infusion 20.3 ± 2.4 12.3 ± 1.1 3.5 ± 0.7 86.0 ± 23.8 4.5 ± 1.0 
Anistreplase 20.2 ± 1.7 15.2 ± 3.1 2.8 ± 1.6t 109.0 ± 23.7t 3.5 ± 1.1 
Streptokinase 20.2 ± 1.9 12.0 ± 3.6 5.3 ± 1.9 89.0 ± 29.5 6.9 ± 1.8 
Urokinase 20.8 ± 1.2 10.3 ± 2.4 4.5 ± 0.5 82.7 ± 13.7 5.3 ± 0.7 
BM 06.022 (46.1% RRH) 21.8 ± 2.2 23.7 ± 4.1t 2.2 ± 0.5t 115.3 ± 11.6t 5.0 ± 1.0 
*Only in dogs with successful reperfusion; cumulative patency time-sum of time intervals in which the coronary artery was patent. tp < 0.05 compared with 
BM 06.022 (10.6% RRH) by the Student t test. Data represent mean values ± SEM; n = 6/group. RRH = residual reactive hyperemia after a 20-s ischemia. 
reactive hyperemia in the dogs treated with BM 06.022 
(Table 2). Accordingly, the number of cyclic flow reductions 
was lower (p < 0.05) after anistreplase and BM 06.022 (50% 
reduction of reactive hyperemia) than after BM 06.022 (90% 
reduction). The cumulative patency time as an indicator of 
flow after reperfusion was also longer (p < 0.05) after 
anistreplase and BM 06.022 (50% reduction of reactive 
hyperemia) than after BM 06.022 (90% reduction). The 
residual thrombus wet weight at termination of the experi-
ment did not significantly differ in any of the fibrinolytic 
groups (Table 2). 
Pharmacokinetic properties (Table 3). After intravenous 
injection of 800 kU/kg (l mg/kg), alteplase achieved an 
initially higher maximal plasma concentration than that of 
BM 06.022 after injection of 140 kU/kg (0.24 mg/kg), but the 
plasma concentration of alteplase declined more rapidly 
because of its shorter (p < 0.05) half-life. The total plasma 
clearance rate of BM 06.022 was 3.3-fold lower (p < 0.05) 
than that of alteplase. Intravenous infusion of alteplase 
produced a plasma concentration lower than that of BM 
06.022 for about 35 min after intravenous injection of BM 
06.022 (Fig. 1). 
Systemic effects (Tables 4 and 5). Residual concentrations 
of fibrinogen, plasminogen and alpha2-antiplasmin were 
lower after treatment with anistreplase and urokinase than 
after treatment with BM 06.022 (p < 0.05), whereas residual 
alpha2-antiplasmin concentration was higher (p < 0.05) after 
streptokinase infusion than after injection of BM 06.022 
(Table 4). The difference in residual alpha2-antiplasmin con-
centration for the two BM 06.022 groups might be explained 
by an extreme value in one group because the median value 
did not differ (55% vs. 54.1%). Residual platelet count did 
not significantly differ between the BM 06.022 and the other 
fibrinolytic groups except the alteplase infusion group, 
whereas the bleeding time at 90 min was longer (p < 0.05) 
after anistreplase, streptokinase and urokinase than after 
BM 06.022 but varied slightly in the two BM 06.022 and 
alteplase groups (Table 4). Significant reduction of the ADP-
induced platelet aggregation was determined only after in-
jection of BM 06.022; collagen-induced platelet aggregation 
was reduced (p < 0.05) after injection of BM 06.022 and 
anistreplase (Table 5). 
Discussion 
Dosage and dose selection. The intravenous bolus dose of 
BM 06.022 used in the present study induced a submaximal 
effect in the study model but was recently shown to be as 
effective as standard treatment with 1 mg/kg of alteplase 
infused over 90 min (7). Therefore, 140 kU/kg of BM 06.022 
given as a single intravenous bolus injection might be a 
reasonable starting dose for clinical trials of the drug in the 
treatment of acute myocardial infarction. Alteplase was 
administered over 3 h at a dose of 1.33 mg/kg, corresponding 
to the infusion protocol for 100 mg rt-PA of the Anglo-
Scandinavian Study of Early Thrombolysis (ASSET) study 
(3). It was also given as a single intravenous bolus injection 
at a dose of 1 mg/kg, which was derived from a previous pilot 
Table 3. Pharmacokinetic Characteristics for t-PA-like Activity of BM 06.022 and Alteplase After Intravenous Bolus Injection in the 
Canine Model of Coronary Artery Thrombosis 
Fibrinolytic 
Agent 
BM 06.022 
Alteplase 
No. of 
Dogs 
5 
6 
Plasma Clearance 
(ml·min- 1·kg- 1) 
6.1 ± 0.8 
20.0 ± 1.8* 
AUC (0 to 2 h) 
(IU·h·ml- 1) 
410.9 ± 50.1 
691.0 ± 55.5* 
Cmax (IU/ml) 
1649.0 ± 211.3 
7879.5 ± 515* 
t112 (min) 
9.9 ± 0.6 
3.1 ± 0.3* 
*p < 0.05 compared with BM 06.022 by the Student t test. AUC =area under the plasma concentration versus time curve; Cmax = maximal measured plasma 
concentration; t112 = half-life. Data represent mean values ± SEM. 
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Figure 1. Plasma concentration time profiles for tissue plasminogen 
activator (t-PA) activity after intravenous injection of 140 kU/kg of 
BM 06.022 (circles) (n = 5) and infusion of 1.33 mg/kg of alteplase 
(triangles) (n = 5). Data are mean values ± SEM. 
study (25) with bolus injection of alteplase in patients with 
myocardial infarction to evaluate experimentally the suit-
ability of alteplase for bolus injection. Anistreplase was 
given as a bolus injection of 0.4 U/kg derived from the 
human therapeutic dose of 30 U, as used in the APSAC 
Intervention Mortality Study (AIMS) trial (10). Streptoki-
nase was infused over 60 min at a dose of 21,000 IU/kg, as 
was practiced in the Intravenous Streptokinase in Acute 
Myocardial Infarction (I.S.A.M.) study (8). Urokinase was 
administered as a starting bolus dose of 20,000 IU/kg, 
followed by an 89-min infusion of20,000 IU/kg, according to 
the dosing protocol in the German Activator Urokinase 
Study (GAUS) (9). 
Thrombolytic properties. The rate of reperfusion with 
BM 06.022 in the canine model with a high level of obstruc-
tion was 66% (four of six dogs) and was increased to 100% 
(six of six dogs) at a lower level of obstruction, thus 
indicating the high thrombolytic efficacy of this agent in 
contrast to that of bolus-injected alteplase and of streptoki-
nase and urokinase in this experimental study. Alteplase 
infusion and anistreplase injection also were highly effective, 
but the most striking difference from BM 06.022 was the 
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. significantly longer time to reperfusion, which was also 
found for streptokinase and urokinase. This property could 
be attributed to the nonfibrin-selective mechanism of action 
of anistreplase, streptokinase and urokinase, which requires 
a longer time for thrombolysis. In the case of alteplase 
infusion, the longer time to reperfusion, which is in accor-
dance with recent experience in this animal model (26), 
might be explained by the low concentration at infusion 
because injection of alteplase accompanied by a higher initial 
plasma concentration also rapidly induced reperfusion. 
The slight variation in the degree of reactive hyperemia 
and the time to occlusion might have influenced the experi-
mental conditions of the study. However, this variation was 
in the range of that reported by other investigators (12,26) 
and the total duration of occlusion before therapy was 
constant at 1 h. 
For practical reasons (five different agents), the study was 
performed in an open label fashion, which could have 
induced a bias. However, the results demonstrated good 
reproducibility for BM 06.022 compared with that obtained 
in the previous dose-ranging study (7). Because experimen-
tal studies with pretreatment or concomitant treatment with 
heparin demonstrated enhancement of thrombolysis with 
rt-PA (27) and streptokinase (12,28), all dogs were heparin-
ized in the present study. However, it remains to be inves-
tigated whether heparin enhanced the thrombolysis with BM 
06.022. 
Evaluation of the experimental model. The assessment of 
the thrombolytic properties of a fibrinolytic agent strongly 
depends on the model used. The model employed in this 
study is known to develop a thrombus that has a platelet-rich 
fibrin head and a red tail (13) or a complex structure 
(coagulation of fibrin and platelets) (11) and, therefore, is 
more resistant to lysis than is a fibrin-rich thrombus like that 
in a copper coil model (29). Furthermore, platelet aggrega-
tion seems to be involved in the spontaneous reocclusion 
observed in this model (11). In addition, the assessment 
depends on the definition of the variables; for example, 
Jackson et al. (30) defined reocclusion "as zero coronary 
Table 4. Hemostatic Variables, Platelet Count and Bleeding Time in the Canine Model of Coronary Artery Thrombosis 
Residual Residual Residual ar Residual 90-min 
Fibrinogen Plasminogen Antiplasmin Platelet Count Bleeding Time 
Fibrinolytic Agent (%) (%) (%) (%) (min) 
BM 06.022 (10.6% RRH) 95.7 ± 3.7 90.7 ± 3.6 52.2 ± 6.5 111.8 ± 4.8 2.5 ± 0.2 
Alteplase 
Injection 93.0 ± 3.6 88.0 ± 2.2 46.2 ± 5.5 110.8 ± 9.8 2.5 ± 0.2 
Infusion 97.2 ± 3.3 88.9 ± 2.8 72.3 ± 2.2* 97.1 ± 2.4* 3.8 ± 0.9 
Anistreplase 4.3 ± 0.2* 45.6 ± 2.4* 17.0 ± 5.4* 99.9 ± 8.4 13.5 ± 4.3* 
Streptokinase 101.1 ± 3.5 88.5 ± 1.9 71.5 ± 3.1* 113.4 ± 6.6 9.5 ± 2.5* 
Urokinase 26.2 ± 11.5* 64.7 ± 3.0* 15.4 ± 2.3* 105.2 ± 6.6 6.3 ± 2.0* 
BM 06.022 (46.1% RRH) 98.8 ± 5.8 85.9 ± 2.7 71.0 ± 12.9 109.6 ± 6.3 3.5 ± 0.3* 
*p < 0.05 compared with BM 06.022 (10.6% RRH) by Student's ttest. Data represent mean values± SEM; n = 6/group. Residual concentrations ofhemostatic 
variables or residual platelet count were determined 2 h after initiation of fibrinolytic treatment as % of baseline. RRH = residual reactive hyperemia after 20 s 
of ischemia. 
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Table 5. Platelet Aggregation Before and After Fibrinolytic Treatment in the Canine Model of Coronary Artery Thrombosis 
ADP-Induced Platelet Aggregation(%) Collagen-Induced Platelet Aggregation(%) 
Fibrinolytic Agent No. Before 2h No. Before 2h 
BM 06.022 (10.6% RRH) 5 76.1 ± 4.2 73.1 ± 5.4* 4 69.8 ± 9.9 53.4 ± 9.8 
Alteplase 
Injection 6 75.2 ± 3.1 76.7 ± 3.2 6 78.3 ± 2.2 80.2 ± 3.9 
Infusion 5 86.0 ± 3.4 83.3 ± 4.7 3 84.0 ± 6.4 81.3 ± 4.8 
Anistreplase 3 71.1 ± 10.0 35.4 ± 22.9 4 69.2 ± 5.4 17.6 ± 17.5* 
Streptokinase 6 63.4 ± 2.6 60.8 ± 5.9 4 66.3 ± 4.7 48.3 ± 15.3 
Urokinase 6 69.0 ± 2.2 60.4 ± 7.4 4 72.0 ± 8.1 59.8 ± 20.4 
BM 06.022 (46.1% RRH) 5 64.5 ± 6.8 48.6 ± 5.2* 5 81.0 ± 3.2 66.4 ± 5.1* 
*p < 0.05 compared with the control value before treatment by the Student paired t test. Data represent mean values± SEM. ADP= adenosine diphosphate; 
RRH = residual reactive hyperemia following a 20-s period of ischemia. 
blood flow that persisted for 30 minutes or longer,'' whereas 
we defined it as zero flow after reperfusion, regardless of 
how long this period lasted. Therefore, reocclusion is an 
intrinsic feature of the model. 
A spontaneous reocclusion rate of 86% (17) or 89% (26) 
for heparinized dogs receiving an infusion of rt-PA was 
recently reported from studies using this model. 
The time to reocclusion was 10.3 ± 3.1 min for rt-PA (26) 
and, therefore, comparable to the results obtained with the 
fibrinolytic agents in the present study. In most of our study 
dogs, reocclusion did not occur as a permanent zero flow, 
but rather as typical cyclic flow reductions after successful 
lysis (17). Because ofthis phenomenon, which was observed 
in all groups, no significant difference in the residual throm-
bus wet weight among the groups treated with the different 
fibrinolytic agents was found. The maximal value of coro-
nary blood flow after reperfusion was similar in all treatment 
groups; for BM 06.022, it was only improved at an experi-
mental setting with a lower level of obstruction. Thus, 
intravenous bolus injection of BM 06.022 rapidly induced a 
high rate of reperfusion, but the general problem of reocclu-
sion was not solved. 
Comparison with other t-PA mutants. A recent study (29) 
using a dog model of copper coil-induced coronary artery 
thrombosis evaluated two variants of t-PA consisting of the 
kringle-2 and protease domains of t-PA as in BM 06.022. In 
contrast to BM 06.022, which is unglycosylated because of 
its expression in E. coli cells, these variants were partially or 
completely unglycosylated because of point mutation of the 
glycosylation sites and were expressed in a mammalian cell 
system. The partially glycosylated deletion variant (aspara-
gine-184 altered to glutamine through mutagenesis) was 
shown to have a markedly slower clearance rate (27 to 39 vs. 
320 to 540 ml/min) than rt-PA. Consequently, equivalent 
doses had a higher thrombolytic potency than did rt-PA. A 
glycosylated variant of t-PA also consisting of the kringle-2 
and protease domains of t-PA was investigated (30) in a 
canine model of coronary artery thrombosis induced by 
electrolytic injury. This variant was found to be a more 
effective agent than rt-PA. In comparison with these deletion 
mutants of t-PA, BM 06.022 also reveals an increased 
potency in the range of the results obtained in these previous 
studies. 
Pharmacokinetic properties. Despite a lower specific ac-
tivity of BM 06.022 in vitro, the pharmacodynamic results 
demonstrate a higher in vivo thrombolytic potency of BM 
06.022 compared with alteplase. The lower effectiveness of 
alteplase after bolus injection appeared to depend on the 
more rapid decline of the initially very high alteplase plasma 
concentration than that of BM 06.022. This finding might be 
explained by the 3.3-fold lower plasma clearance rate of BM 
06.022, which is lacking the fingerlike, growth factorlike and 
kringle-1 domain oft-PA and all oligosaccharide side chains. 
The pharmacokinetic findings of this study for alteplase are 
comparable with previous results with rt-PA (31) and for BM 
06.022 with results with deletion mutants (29). The slower 
plasma clearance of BM 06.022 allowed a dose reduction, 
achieving a similar area under the curve value as with 
alteplase at a higher dose. A recent dose-ranging study (32) 
in healthy human volunteers showed that the systemic 
clearance of BM 06.022 was 306 ± 40 ml (corresponding to 
4 ml·min- 1·kg- 1) using the same plasminogen activator 
assay as described in the present study. The clearance rate 
for t-PA activity in human volunteers (33) was 1,235 ± 
170 ml/min (corresponding to 14.9 ml·min- 1·kg- 1). Bolus 
injection of BM 06.022 might also have impact on the safety 
of this agent because the presence of BM 06.022 in plasma is 
restricted to approximately lOO min (Fig. 1), which is long 
enough for thrombolysis, whereas alteplase plasma concen-
tration is maintained for 3 h by infusion. A short presence in 
plasma could favor the reduction of bleeding complications. 
Systemic effects. Effects of BM 06.022 and alteplase on 
hemostasis proteins were comparably low, indicating a com-
parable degree of fibrin selectivity at similar plasma concen-
trations. The effect of streptokinase on fibrinogen, plasmi-
nogen and alpha2-antiplasmin in the dog was low as 
previously reported (34,35), probably because the species-
specific systemic activation of canine plasminogen is lower 
than that of human plasminogen. Significant reduction of 
fibrinogen, plasminogen and alpha2-antiplasmin was seen for 
anistreplase and urokinase, confirming previous findings 
with urokinase in dogs (35,36). It must be noted that the 2-h 
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determination of the hemostasis variables is only a snapshot; 
later determinations could differ because of prolonged action 
or infusion of some fibrinolytic agents. In all treatment 
groups, platelet count virtually was not reduced, but the 
90-min bleeding time was significantly prolonged in the 
anistreplase, streptokinase and urokinase groups. This might 
be explained by the extensive fibrinogen reduction induced 
by anistreplase or the administration of the nonfibrin-
selective fibrinolytic agents by infusion. The additional in-
hibitory effect of anistreplase on platelet aggregation as 
observed in the present study and recently reported by Fears 
et al. (37) might explain the greatest prolongation of the 
bleeding time in this group. Significant inhibition of platelet 
aggregation was also found for BM 06.022 but was less 
marked than for anistreplase. Because there was some 
variability in the determination of the bleeding time (for 
example, between the two BM 06.022-groups) and because 
the study was performed unblinded, only large differences in 
bleeding time prolongation should be regarded as relevant. 
Individual dogs in every group with fibrinolytic treatment 
demonstrated spontaneous bleeding from surgical wounds 
after treatment. However, no apparent differences among 
the agents were detected. 
Conclusions. Comparative evaluation of BM 06.022 re-
sulted in a pharmacologic profile that might combine the 
advantages and avoid some of the disadvantages of the 
reference fibrinolytic agents. BM 06.022 rapidly achieved a 
high reperfusion rate without inducing a systemic lytic state 
in the dog. 
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